NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) — According to Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, conclusions cited in the May 15, 2016, New York Times Magazine article, “An Old Idea, Revived: Starve Cancer to Death,” support the science behind its proprietary compound, SM-88.
The Times article describes the original research conducted by Nobel Prize winner Otto Warburg on what is effectively cancer cells’ damaged metabolic reliance on glucose rather than more efficient respiration involving oxygen. While Warburg’s work was generally praised, his discoveries were soon overshadowed by new discoveries in gene therapy. However, as the article points out, “Even James Watson, one of the fathers of molecular biology, is convinced that targeting metabolism is a more promising avenue in current cancer research than gene-centered approaches.” Ultimately, experts agree that this may be the key to cancer’s vulnerability.
“We find it very promising that the scientific community is focused on the potential of this type of cancer-fighting therapy and has validated the importance of targeting cancer cell metabolism. SM-88 is a drug candidate with a unique metabolic approach, and this timely article is especially encouraging in highlighting the latest scientific thinking,” said Michael Demurjian, Chief Operating Officer, Tyme Technologies.
Late last year, Tyme submitted a Phase 2 Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for SM-88, which is designed to synergistically target the unique metabolic features of cancer cells and selectively alter the susceptibility of cancer cells to oxidative stress. Tyme is currently in discussions with the FDA regarding advancing SM-88.
Tyme is currently focused on commencing its next round of clinical studies with a study in prostate cancer by the third quarter of 2016. This will be part of a program of multiple studies of SM-88 across various indications, including those in breast and pancreatic cancers. Tyme has previously reported activity in women’s cancers including breast cancer.
About Tyme
Tyme’s research and development efforts are based on a proprietary platform technology, for which it retains global Intellectual Property (IP) and commercial rights. SM-88 is believed to be a first-in-class oncology therapy that increases the power of the body’s innate defenses to utilize oxidative stress to kill cancer cells. It is designed to penetrate only living cancer cells without toxic effects and without involving healthy body tissue. Its therapeutic potential is based on its ability to increase the availability of free radicals and promote their entry into cancer cells by stripping the cancer cells of their normal barriers to these toxic electrons. SM-88 is a combination of a proprietary novel molecule with three currently marketed drugs that are generally considered safe for their already-approved indications in areas other than cancer treatment.
For more information, visit: www.tymetechnologiesinc.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding Tyme’s future performance, and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. Forward-looking statements within this press release include, without limitation, statements regarding our drug development strategies, the therapeutic mechanisms of our drug candidates and our completed and planned clinical trials. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).
Contact:
Lisa M. Wilson,
In-Site Communications, Inc.
lwilson@insitecony.com
917-543-9932
